Literature DB >> 15867875

Has the cost-effectiveness of Xolair (omalizumab) been underestimated?

Carl V Asche, Diana I Brixner, Gary M Oderda.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15867875     DOI： 10.1016/j.jaci.2004.12.1136

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  1 in total

1.  Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model.

Authors:  Ann C Wu; A David Paltiel; Karen M Kuntz; Scott T Weiss; Anne L Fuhlbrigge
Journal:  J Allergy Clin Immunol       Date:  2007-09-29       Impact factor: 10.793
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.